Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

- Conference Call Today at 5:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the first quarter ended March 31, 2008.

"During the first quarter, we made significant progress in moving our clinical trials forward and generating data to demonstrate the potential of picoplatin as a new generation platinum therapy," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "Our pivotal Phase 3 SPEAR trial in small cell lung cancer continues to enroll patients. Today, we are pleased to announce the completion of patient enrollment in our Phase 2 trial in metastatic colorectal cancer. The results of our Phase 1 trials in prostate cancer and colorectal cancer were presented earlier this year. Encouraging bioavailability data has been presented from our ongoing Phase 1 trial of oral picoplatin. We secured commercial manufacture and supply of picoplatin drug substance. A new chief medical officer was appointed to expedite the clinical development of picoplatin through product approval. Our accomplishments this quarter are consistent with the development of picoplatin as a platform product addressing multiple indications, combinations and formulations."

First Quarter and Recent Highlights

Picoplatin and Development Pipeline

* Small Cell Lung Cancer: Presented final data from our Phase 2 trial

of picoplatin in small cell lung cancer (SCLC) at the International

Association for the Study of Lung Cancer and the European Society

for Medical Oncology's 1st European Lung Canc
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... July 24, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... Potassium Sulphate basic information, including its definition, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... entrepreneurship http://www.draperuniversity.com , is proud to announce ... entrepreneurs from 17 different countries will converge on ... Silicon Valley for an intensive, experiential program focused ... doing.” The highly selective school, currently running its ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... Makes it Easy to Connect with Technology ... on Specific Chemical Reactions, PRINCETON, N.J., July ... portal for manufacturers that require service,and support in ... bio-technology products, industrial products and,higher-value chemicals. The all-new ...
... July 14 Vermillion, Inc.,(Nasdaq: VRML ), ... engaged ThinkPanmure LLC., a global, growth-company investment bank, ... alternatives,intended to enhance the potential of the Company,s ... biomarkers to,maximize stockholder value. No assurances can be ...
... Cardium Therapeutics,(Amex: CXM ) and its ... InnerCool,s RapidBlue(TM) endovascular temperature modulation,system conforms to ... use in,inducing, maintaining and reversing mild hypothermia ... arrest, neurosurgery, fever,cardiovascular re-warming, trauma re-warming, and ...
Cached Biology Technology:Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 3Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives 2Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 2Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 3Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 4Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 5Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 6Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 7Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification 8
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... 24, 2014(BRONX, NY)Researchers at Albert Einstein College of ... from The Michael J. Fox Foundation for Parkinson,s Research ... for Parkinson,s disease. This drug discovery project will test ... goal of developing a drug that acts on an ... therapies for Parkinson,s help many people manage their symptoms, ...
(Date:7/24/2014)... counterparts in humans, affect the connections between nerve cells ... hippocampus, an area of the brain that plays a ... memories. The results of the study have been published ... depends on the active communication between nerve cells, known ... into a dense network where they constantly relay signals ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... marketed as plant growth enhancers are becoming increasingly ... small companies with limited research capabilities, have not ... about product effectiveness been documented by scientific data. ... growth regulatory effect of Tea Seed Powder (TSP), ...
... in the adult human body are genetically identical, but develop ... or neurons, by activating some genes while inhibiting others. Remarkably, ... by remembering which genes should be kept on or off, ... is not written directly into the DNA, yet it is ...
... a defense against predators or pathogens. Some are also used ... in medicines. As recently as the early 1990s, a unique ... discovered. First noted through African tribal use as a ... since been determined to serve as a powerful insecticidal and ...
Cached Biology News:Plant growth affected by tea seed powder 2Making copies at the right time 2Making copies at the right time 3Cellular processing of proteins found in Congolese child birthing tea now revealed 2Cellular processing of proteins found in Congolese child birthing tea now revealed 3Cellular processing of proteins found in Congolese child birthing tea now revealed 4
Request Info...
... Quickly, effectively seals labware. Waterproof, moisture-proof ... anhydrous materials. Can be folded repeatedly ... rupturing. Stretched lengthwise at 21C (70F), ... when tension is removed, film only ...
...
Normal human AB serum, pooled...
Biology Products: